Educational guide
Selank: Anxiolytic Peptide Research | Palmetto Peptides
Selank: Anxiolytic Peptide Research Research Notice: This article covers research on Selank research peptide and Semax research peptide — available from Palmetto Peptides for laboratory use only. Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro)
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Selank: Anxiolytic Peptide Research
Research Notice: This article covers research on Selank research peptide and Semax research peptide — available from Palmetto Peptides for laboratory use only.
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a stable analog of the endogenous immunomodulatory tetrapeptide Tuftsin (Thr-Lys-Pro-Arg). The addition of a C-terminal Pro-Gly-Pro sequence borrowed from melanocyte-stimulating hormone improves metabolic stability and extends the compound's biological activity window. Selank has been studied extensively for anxiolytic, nootropic, and immunomodulatory properties and holds regulatory approval in Russia for the treatment of generalized anxiety disorder.
Last Updated: February 22, 2026 | Reading Time: Approximately 6 minutes | Author: Palmetto Peptides Research Team
Quick Answer
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a stable analog of the endogenous immunomodulatory tetrapeptide Tuftsin (Thr-Lys-Pro-Arg).
Structure and Development
Selank's parent compound, Tuftsin, is a naturally occurring tetrapeptide cleaved from the Fc portion of IgG immunoglobulin. Tuftsin is known to stimulate phagocytosis, natural killer cell activity, and overall immune surveillance. The Selank modification retains the Tuftsin core while adding CNS-active extensions that confer blood-brain barrier penetration and neuropeptide activity beyond immunomodulation.
The resulting heptapeptide demonstrates a unique dual research profile: immunomodulatory activity through Tuftsin receptor interactions and anxiolytic/nootropic activity through GABAergic and serotonergic modulation. This positions Selank as an important research tool for studying the immunological basis of anxiety and the neurobiological overlap between immune function and cognitive performance.
Mechanism of Action
GABAergic System Modulation
Research has identified interaction with the GABA-A receptor complex as a key mechanism underlying Selank's anxiolytic properties. Unlike benzodiazepines, which are positive allosteric modulators of GABA-A receptors and carry risks of tolerance and dependence, Selank's mechanism of GABAergic modulation appears to involve indirect modulation of GABA system activity without direct benzodiazepine receptor binding. This distinction has significant implications for understanding anxiolytic mechanisms that may be free from the pharmacological liability profile of classical benzodiazepines.
Enkephalinase Inhibition
Research has shown that Selank inhibits enkephalinase — the enzyme responsible for degrading endogenous enkephalin peptides. By preserving enkephalin activity, Selank may modulate endogenous opioidergic tone, contributing to anxiolytic and analgesic effects observed in animal models. This mechanism represents a distinct approach to studying endogenous pain and anxiety regulation.
Serotonergic and Dopaminergic Involvement
Animal studies have documented Selank-induced changes in serotonin and dopamine metabolism in limbic brain regions including the hippocampus, amygdala, and prefrontal cortex. These findings suggest modulation of monoaminergic neurotransmission may contribute to both the anxiolytic and cognitive effects reported in research.
BDNF Expression
Similar to Semax, research has documented Selank's ability to modulate BDNF expression in the hippocampus and prefrontal cortex. However, Selank's BDNF effects appear secondary to its anxiolytic/immunomodulatory primary profile, whereas BDNF upregulation is considered central to Semax's research identity.
Research Findings
Anxiolytic Effects in Animal Models
Rodent studies using elevated plus maze, open field, and social interaction paradigms consistently demonstrate anxiolytic effects of Selank. Research by Semenova et al. documented reduced anxiety-like behavior in rats at doses that did not impair locomotor activity, suggesting a favorable separation between anxiolytic and sedative effects. This profile has been compared favorably to diazepam in preclinical research, with Selank showing equivalent anxiolysis without the sedation, muscle relaxation, or tolerance development associated with benzodiazepines.
Immunomodulatory Research
Selank's Tuftsin-derived sequence drives significant research into immune function. Studies have documented enhanced natural killer cell activity, increased interleukin-2 production, and modulation of T-cell proliferative responses. Research examining Selank's immunological effects has explored its potential as a research tool for studying stress-induced immunosuppression, as anxiety and immune dysfunction frequently co-occur clinically.
Cognitive Effects Under Stress
A distinctive aspect of Selank's research profile is its ability to preserve or enhance cognitive performance under conditions of stress. Animal studies using models of acute and chronic psycho-emotional stress have found that Selank pretreatment attenuates stress-induced impairments in memory and attention tasks. This stress-resilience aspect of Selank's research profile distinguishes it from purely sedating anxiolytics and has driven interest in the compound as a model for studying anxiolytic compounds with nootropic properties.
Research Protocols
Selank is commonly administered intranasally in research settings, utilizing the olfactory pathway for CNS delivery. This route achieves meaningful brain concentrations while avoiding extensive first-pass hepatic metabolism. Research protocols in animal models typically use intranasal or subcutaneous administration, with cognitive and anxiety assessments performed at defined time points post-administration.
Selank is often studied in comparison to or combination with Semax, as the two peptides share a neuropeptide heritage while having complementary pharmacological profiles — Semax more activating/pro-cognitive, Selank more anxiolytic/immunomodulatory. Storage of lyophilized Selank requires protection from moisture and UV light; refrigeration is recommended for reconstituted solutions.
Selank vs. Semax: Research Comparison
Primary effect: Selank → anxiolytic/immunomodulatory; Semax → stimulating/pro-cognitive
GABAergic activity: Selank shows indirect GABAergic modulation; Semax does not significantly modulate GABA systems
BDNF upregulation: Both increase BDNF; effect is more pronounced and primary in Semax research
Clinical approval: Both hold Russian regulatory approval for neurological/psychiatric conditions
Immunomodulation: Selank has significant Tuftsin-derived immune effects; Semax's immune profile is less prominent
Frequently Asked Questions
How does Selank produce anxiolytic effects without benzodiazepine receptor binding?
Research suggests Selank modulates GABAergic tone indirectly — potentially by influencing GABA receptor expression or through enkephalinase inhibition that preserves endogenous anxiolytic peptide activity. The precise molecular mechanism continues to be an active area of investigation.
Why is the Tuftsin sequence significant in Selank research?
Tuftsin is an endogenous immunostimulant derived from IgG, giving Selank a natural biological precedent for its immune-modulating effects. This connection between the adaptive immune system and anxiolytic peptide biology is a unique aspect of Selank research with broader implications for psychoneuroimmunology.
What is the half-life of Selank?
Native Tuftsin is rapidly degraded in plasma. The Pro-Gly-Pro extension in Selank confers substantially greater metabolic stability, though the compound is still considered relatively short-acting. Research protocols account for this by timing behavioral assessments appropriately relative to administration.
References
Semenova TP, et al. (2009). Selank and its analogs modulate the expression of genes involved in immune and nervous system function. Bulletin of Experimental Biology and Medicine. PMID: 20023852
Filatova EV, et al. (2007). Effects of Selank on monaminergic brain systems in rats. Eksperimental'naia i Klinicheskaia Farmakologiia. PMID: 17941263
Mjasoedov NF, et al. (1999). Behavioral activity of Selank on models of anxiety. Zhurnal Vysshei Nervnoi Deiatelnosti Imeni I P Pavlova. PMID: 10349684
Disclaimer: All compounds offered by Palmetto Peptides are strictly for laboratory research and in vitro studies. They are not intended for human consumption, veterinary use, or any therapeutic application. All information provided is for educational and scientific reference only. Palmetto Peptides makes no health claims. Consult a licensed medical professional before handling any research compound.
Related Research: Semax: Nootropic Peptide Research Guide | Top 10 Peptides of the Future: What Research Suggests | Why Peptides Matter in Research: A Scientific Perspective
Related Research
Cognitive Performance: Natural Evidence-Based Approaches
Semax: Nootropic Peptide Research Guide
Related research: selank complete research guide, selank vs semax research comparison, and semax vs selank comparison.
More Research Articles
Where to Buy High-Purity Sermorelin Research Peptide: Quality and Supplier Guide
Jul 8, 2026